Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment

G D Pountain, M T Keogan, D L Brown, B L Hazleman

Abstract

Objectives—Some reports have described a decreased percentage of circulating CD8+ cells in patients with polymyalgia rheumatica and giant cell arteritis (PMR/GCA) before treatment and persisting for some months during treatment with corticosteroids. Other studies have found no such changes. There are overt methodological variations between these studies and there may also be hidden differences, such as the timing of blood samples. The purpose of this study was to investigate T cell subtypes in patients with PMR/GCA while controlling for variables known to affect T cells.

Methods—Circulating T cell subsets were measured in 36 patients with PMR/GCA before and during treatment with prednisolone. Blood samples during treatment were taken before the daily dose of prednisolone. The whole blood lysis method was used followed by flow cytometry.

Results—Compared with controls, CD8+ cells were not reduced before treatment in patients with PMR/GCA (0·44×10^6/l; 28% of lymphocytes). CD4+ cells were also normal (0·78×10^6/l; 48% of lymphocytes). During treatment with prednisolone total T cells increased from 1·18 to 1·59×10^6/l and CD4+ cells increased from 0·78 to 1·05×10^6/l. The percentage of CD8+ cells decreased on treatment from 28 to 25%.

Conclusions—This study does not confirm the finding of some groups that the percentage of circulating CD8+ cells is reduced in patients with PMR/GCA before treatment. It does show that the percentage of CD8+ cells decreases during treatment with corticosteroids. This needs to be considered when designing studies of lymphocyte subsets in diseases treated with corticosteroids.

(Ann Rheum Dis 1993; 52: 730–733)
Variation in CD8+ cells with treatment in PMR/GCA

percentage of lymphocytes do not change significantly in the first few hours, but with longer term prednisolone treatment this percentage decreases significantly. Hence corticosteroid treatment alters the T cell subtypes depending on the timing of the sample.

To clarify the conflicting data from previous work, this study was designed to eliminate these variables.

**Patients and methods**

Thirty six patients with PMR/GCA were assessed before, during, and after treatment with prednisolone. Ages ranged from 51 to 87 years (median 70 years). Diagnosis was made according to the clinical criteria of Jones and Hazleman. Increased erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) were not used as inclusion criteria, as these and other laboratory variables were to be studied, but in fact 34 of 36 patients did have an ESR above 30 mm/h or a CRP above 6 mg/l, or both. Serum creatine kinase and protein electrophoresis were normal in all patients with PMR.

These patients had blood samples taken between 1000 and 1400 hours, before treatment, and subsequently after 10 days, three weeks, six weeks, and three months of treatment, and thereafter every three months until treatment could be discontinued. Venesection was always carried out at the same time of day and before the daily prednisolone dose. Treatment for PMR was begun with prednisolone 10–20 mg daily, or for GCA with prednisolone 40 mg daily. Prednisolone was prescribed as the enteric coated preparation and as a once daily dose in the morning. Subsequently the dose was reduced according to clinical disease activity.

Controls were matched for age and sex and consisted of healthy volunteers and patients with osteoarthritis. Ethical committee approval was obtained to approach the controls for blood tests. Control samples were collected between 1000 and 1400 hours.

All patients and controls were seen at Addenbrooke’s Hospital and all blood samples were processed within six hours of venesection. The total white blood cell count and lymphocyte count were measured using routine techniques in the haematology department at Addenbrooke’s Hospital. T cell subtypes were analysed by flow cytometry using a whole blood lysis technique. Total T cells were measured using antibodies to CD3 (Leu 4). Activated T cells were those CD3+ cells which coexpressed antibodies to HLA-DR. CD4+ cells were defined using Leu 3 and CD8+ cells using Leu 2. Natural killer cells were CD3- expressing CD 16/56 (Leu 11c+19). All monoclonal antibodies were purchased from Becton Dickinson (Oxford, United Kingdom) from the Simulset range. Aliquots of blood were incubated with antibody pairs for dual staining for 15 minutes at room temperature. Erythrocytes were lysed using FACS lysing solution (Becton Dickinson) and leucocytes were fixed with 0·5% formaldehyde. Cells were analysed on the day of processing using a Becton Dickinson FACSscan and Simulset software. This software analyses the lymphocyte gate and corrects the subsequent analysis for non-lymphocyte events.

Pretreatment values for lymphocyte subsets in the 36 patients with PMR/GCA were compared with controls. In addition, to see if patient selection was a critical factor, the patients with biopsy-proved GCA or the most severe symptoms of PMR, or both, were considered separately. This group of 13 was compared with controls and with the remaining group of 23 patients with less severe GCA/PMR.

Statistical analysis consisted of the Mann-Whitney test to compare groups and paired analysis by the Wilcoxon test to examine within patient changes in T cell subsets.

**Results**

In all 36 patients with PMR/GCA before prednisolone treatment, lymphocytes, T cells, and T cell subtypes were all normal compared with controls (table 1).

After 10 days and three weeks of prednisolone treatment the absolute numbers of lymphocytes, T cells, and CD4+ cells had increased significantly, whereas CD8+ cells as a percentage of lymphocytes had decreased significantly (table 1).

The two year follow up of CD8+ cells is shown in the figure.

![Graph A](attachment://GraphA.png)

**Graph A** Comparison of CD8+ cells (% of lymphocytes) in patients with polymyalgia rheumatica and giant cell arteritis (PMR/GCA) before and during treatment with prednisolone.

**Graph B** Comparison of CD8+ cells (x10^6/l) in patients with polymyalgia rheumatica and giant cell arteritis (PMR/GCA) before and during treatment with prednisolone.
Table 1 Lymphocytes and lymphocyte subtypes in controls and patients with polymyalgia rheumatica (PMR/GCA) before treatment and after three weeks of treatment with prednisolone. Results expressed as medians, in absolute numbers, and as a percentage of lymphocytes

<table>
<thead>
<tr>
<th>Parameter measured</th>
<th>Controls (n=36)</th>
<th>Patients with PMR/GCA before treatment (n=36)*</th>
<th>Patients with PMR/GCA after three weeks of treatment (n=34)**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphocytes (×10^9/l)</td>
<td>1.67</td>
<td>1.47 (NS)</td>
<td>2.19 (p&lt;0.005)</td>
</tr>
<tr>
<td>Total T cells (%)</td>
<td>1.10</td>
<td>1.18 (NS)</td>
<td>1.59 (p=0.007)</td>
</tr>
<tr>
<td>CD4+ cells (%)</td>
<td>46.5</td>
<td>48 (NS)</td>
<td>71 (NS)</td>
</tr>
<tr>
<td>CD8+ cells (%)</td>
<td>0.49</td>
<td>0.44 (NS)</td>
<td>0.49 (NS)</td>
</tr>
<tr>
<td>CD4+/CD8+ ratio</td>
<td>1.59</td>
<td>1.74 (NS)</td>
<td>1.92 (p&lt;0.006)</td>
</tr>
<tr>
<td>Activated T cells (%)</td>
<td>0.12</td>
<td>0.11 (NS)</td>
<td>0.13 (NS)</td>
</tr>
<tr>
<td>NK cells (%)</td>
<td>6.5</td>
<td>8 (NS)</td>
<td>6 (NS)</td>
</tr>
<tr>
<td>(x10^9/l)</td>
<td>0.23</td>
<td>0.22 (NS)</td>
<td>0.17 (NS)</td>
</tr>
<tr>
<td>(x10^9/l)</td>
<td>13</td>
<td>15 (NS)</td>
<td>8 (p=0.027)</td>
</tr>
</tbody>
</table>

*Values in parentheses are p values compared with controls.
**Values in parentheses are p values compared with pretreatment results.

Table 2 Lymphocytes and lymphocyte subtypes in the patients with most severe polymyalgia rheumatica and giant cell arteritis (PMR/GCA) compared with controls and with patients with less severe PMR/GCA. Results expressed as medians, in absolute numbers, and as a percentage of lymphocytes

<table>
<thead>
<tr>
<th>Parameter measured</th>
<th>Controls (n=36)</th>
<th>Patients with severe PMR/GCA before treatment (biopsy proved GCA or severe PMR, or both) (n=13)*</th>
<th>Patients with less severe PMR/GCA before treatment (n=23)**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphocytes (×10^9/l)</td>
<td>1.67</td>
<td>1.42 (p=0.048)</td>
<td>1.72 (NS)</td>
</tr>
<tr>
<td>Total T cells (%)</td>
<td>1.10</td>
<td>1.05 (NS)</td>
<td>1.24 (NS)</td>
</tr>
<tr>
<td>CD4+ cells (%)</td>
<td>68.5</td>
<td>71 (NS)</td>
<td>71 (NS)</td>
</tr>
<tr>
<td>CD8+ cells (%)</td>
<td>0.75</td>
<td>0.71 (NS)</td>
<td>0.80 (NS)</td>
</tr>
<tr>
<td>CD8- cells (%)</td>
<td>45</td>
<td>50 (NS)</td>
<td>47 (NS)</td>
</tr>
<tr>
<td>CD4+/CD8+ ratio</td>
<td>0.49</td>
<td>0.36 (p=0.037)</td>
<td>0.48 (NS)</td>
</tr>
<tr>
<td>Activated T cells (%)</td>
<td>0.12</td>
<td>0.14 (NS)</td>
<td>0.11 (NS)</td>
</tr>
<tr>
<td>NK cells (%)</td>
<td>6.5</td>
<td>9 (NS)</td>
<td>8 (NS)</td>
</tr>
</tbody>
</table>

*Values in parentheses are p values compared with controls.
**Values in parentheses are p values compared with patients with severe PMR/GCA.

We considered the group with severe PMR/GCA separately (table 2); this group had reduced lymphocyte and reduced CD8+ numbers before treatment compared with controls. CD8+ cells as a percentage of the lymphocytes were not reduced, however. The subgroup of three patients with biopsy-proven GCA was too small for separate statistical analysis but their CD8+ counts were similar to the subgroup with severe PMR (as absolute numbers and as a percentage of lymphocytes).

Discussion

The results of this study do not confirm the conclusions of some previous studies that CD8+ cells are reduced in patients with GCA/PMR before treatment but agree with the studies of Andersson et al and Banks et al in finding no abnormality before treatment. Our previous finding that the percentage of CD8+ cells decreases significantly on treatment with prednisolone illustrates the importance of ensuring that initial samples are obtained before treatment is begun. In practice, this is often difficult, as any delay in the treatment of PMR/GCA may lead to irreversible complications such as blindness. Hence recruiting untreated patients is not easy. We found that several patients seen rapidly for their first assessment and assumed to have received no corticosteroids had actually received the initial dose of prednisolone from their family doctor, and therefore were excluded from our study. This clinical history must be diligently sought and the magnitude of the effect of a single dose of corticosteroids appreciated.

Our work in normal volunteers has shown that the effects of prednisolone on lymphocyte subtypes occur in two phases. The initial effects (maximum at about seven hours after a 20 mg dose of enteric coated prednisolone) include a pronounced decrease in the absolute numbers of lymphocytes, total T cells, CD4+, and CD8+ cells. The effects of longer term prednisolone treatment are almost the opposite of the early effects—that is, at 72 hours the absolute numbers of total T cells, CD4+, and CD8+ cells are markedly increased, with a decrease in the percentage of CD8+ cells. These later effects begin to develop by 24 hours after the first dose of prednisolone. Before this study only acute lymphopenia (particularly of CD4+ cells) had been shown after a single dose of prednisolone in volunteers. The same effect has been assumed by some to occur in longer term treatment with corticosteroids, whereas our study in normal volunteers shows that the later changes contrast markedly with the acute effects. Those studies in PMR/GCA where patients were already receiving prednisolone at the time of the initial analysis of T cell subtypes cannot give us useful information about CD8+ numbers in PMR/GCA per se. In those studies reporting a reduced percentage of CD8+ cells in PMR/GCA before treatment, the inadvertent inclusion of patients after even a single dose of prednisolone might render these results similarly misleading. Multicentre studies may be particularly prone to this factor, in that it is more difficult at a distance to ensure that no treatment has been given before the initial blood sample.

During follow up of treated PMR/GCA, T cell subtypes will again be critically altered by the interval since the previous dose of prednisolone. In this study T cell subsets during treatment were measured before the daily dose of prednisolone, and this is reflected in the long term increase of CD8+ numbers seen in the figure, though this did not reach statistical significance. Other studies have not referred to the timing of the blood samples. If blood had been taken a few hours after a prednisolone dose, then the absolute numbers of CD8+ cells would be lowered, and if blood had been taken about 24 hours after a dose of prednisolone then CD4+ untreated patients' percentage of lymphocytes would be lowered. Hence studies reporting prolonged lowering of CD8+ cells in PMR/GCA may be showing the effects of prednisolone rather than the effects of PMR/GCA per se.
Variation in CD8+ cells with treatment in PMR/GCA

Some differences in the results of studies in patients with PMR/GCA might be due to patient selection. In our study, an increased ESR and CRP were not required (as these tests were also being investigated). This might have resulted in our patients being less florid than other series, though, in fact, 34 of 36 patients did have either an increased ESR or CRP. We have addressed this problem by separately analysing the data from the most severe cases of PMR together with the cases of GCA proved by biopsy. Although absolute numbers of CD8+ cells were lower in this group, this was part of a slight overall lymphopenia and there was no selective depletion of CD8+ cells. This suggests that studies incorporating only the most severe cases of PMR/GCA may be more likely to show a lowered lymphocyte count and therefore a lowered absolute CD8+ count. CD8+ cells as a percentage of lymphocytes, however, do not seem to be influenced by disease severity. It is therefore unlikely that patient selection accounts for the difference between this study and other studies showing a reduced percentage of CD8+ cells.

The differing results from studies of CD8+ cells in patients with PMR/GCA raises doubts about whether CD8+ cells are actually reduced in these patients. We have illustrated design flaws which could distort data and lead to an erroneous conclusion that CD8+ cells are reduced in PMR/GCA. Published results may also be distorted in favour of an abnormality of CD8+ cells, in that negative studies showing no such abnormality are less likely to be published.19-21 We therefore conclude that the case that CD8+ cells are lowered in patients with PMR/GCA is not proved.

We thank the following for their contribution to the study: MLSOs of the clinical immunology laboratory for evaluation of T cell subtypes; Mrs Sheila Smith for typing the manuscript; Mrs Heather Harman for data entry; and Mrs Greta Humen for the distribution of blood samples.